US6106819A
(en)
*
|
1996-12-31 |
2000-08-22 |
Sucher; David F. |
Methods of treating headache and functional extraocular and intraocular myotendinitis
|
FR2777189B1
(fr)
*
|
1998-04-09 |
2001-04-06 |
Chauvin Lab Sa |
Composition ophtalmique comprenant un beta-bloquant
|
FR2779953B1
(fr)
*
|
1998-06-22 |
2000-08-11 |
Codif International Sa |
Procede d'elaboration d'un produit cosmetique destine a proteger la peau contre les agressions resultant de la pollution de l'air ambiant
|
US6730691B1
(en)
*
|
2000-02-10 |
2004-05-04 |
Miles A. Galin |
Uses of alpha adrenergic blocking agents
|
US8858961B2
(en)
*
|
2000-07-14 |
2014-10-14 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
US20050026924A1
(en)
*
|
2000-07-14 |
2005-02-03 |
Allergan, Inc. |
Compositions containing alpha-2-adrenergic agonist components
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
JP2005521690A
(ja)
*
|
2002-02-22 |
2005-07-21 |
ファルマシア・コーポレーション |
ゴム系を含む眼科用製剤
|
EP2130541A3
(de)
|
2002-07-29 |
2013-12-18 |
Rigel Pharmaceuticals, Inc. |
Verfahren zur Behandlung oder Vorbeugung von Autoimmunerkrankungen mit 2,4-Pyrimidindiaminverbindungen
|
EP2314327B2
(de)
|
2003-05-05 |
2017-09-20 |
Ben-Gurion University Of The Negev Research And Development Authority |
Injizierbare vernetzte polymere zusammensetzung und deren verwendung
|
DE602004032446D1
(de)
|
2003-08-07 |
2011-06-09 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
|
WO2005066337A2
(en)
*
|
2004-01-09 |
2005-07-21 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
|
US20050209606A1
(en)
*
|
2004-02-26 |
2005-09-22 |
Dharmendra Jani |
Alginate viscoelastic composition, method of use and package
|
US20060270592A1
(en)
*
|
2004-03-19 |
2006-11-30 |
Ophthalmic Research Associates, Inc. |
Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
|
CA2505836C
(en)
*
|
2004-05-06 |
2013-08-27 |
Alcon Inc. |
Topical brimonidine tartrate formulations that lack chlorine dioxide
|
US20070004672A1
(en)
*
|
2005-07-01 |
2007-01-04 |
Dharmendra Jani |
Long lasting alginate dry eye, related methods of manufacture and methods of use
|
NZ568694A
(en)
|
2005-11-09 |
2011-09-30 |
Zalicus Inc |
Method, compositions, and kits for the treatment of medical conditions
|
JP2009528295A
(ja)
|
2006-02-24 |
2009-08-06 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jak経路の阻害のための組成物および方法
|
ES2380551T3
(es)
|
2006-11-21 |
2012-05-16 |
Rigel Pharmaceuticals, Inc. |
Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
|
WO2008088612A1
(en)
*
|
2006-12-20 |
2008-07-24 |
Bausch & Lomb Incorporated |
Method of stimulating the production of mucin in the eye of a patient
|
US20080153908A1
(en)
*
|
2006-12-20 |
2008-06-26 |
Jani Dharmendra M |
Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition
|
US7659259B2
(en)
*
|
2006-12-21 |
2010-02-09 |
Bausch & Lomb Incorporated |
Method of treating inflammation of the eye
|
WO2008082948A2
(en)
*
|
2006-12-29 |
2008-07-10 |
Bausch & Lomb Incorporated |
Ophthalmic alginate composition related methods of manufacture and methods of use
|
CA2685230C
(en)
*
|
2007-05-04 |
2012-10-16 |
Bausch & Lomb Incorporated |
Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
|
US20080280853A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Erning Xia |
Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
|
US9125807B2
(en)
|
2007-07-09 |
2015-09-08 |
Incept Llc |
Adhesive hydrogels for ophthalmic drug delivery
|
WO2009105140A2
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
US9096819B2
(en)
|
2008-01-31 |
2015-08-04 |
Bausch & Lomb Incorporated |
Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer
|
US20110046033A1
(en)
|
2008-01-31 |
2011-02-24 |
Jinzhong Zhang |
Multipurpose Lens Care Solution with Benefits to Corneal Epithelial Barrier Function
|
US9481856B2
(en)
*
|
2008-06-09 |
2016-11-01 |
Bausch & Lomb Incorporated |
Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
|
JP2011522863A
(ja)
*
|
2008-06-12 |
2011-08-04 |
ノバルティス アーゲー |
眼の前部に対する持続送達としてのインサイチュゲル化システム
|
CA2736380C
(en)
*
|
2008-09-15 |
2013-05-28 |
Bausch & Lomb Incorporated |
Compositions comprising polymers having amino sugar units and methods of making and using same
|
US20100087550A1
(en)
|
2008-10-06 |
2010-04-08 |
Zora Marlowe |
Formulations with a Tertiary Amine Oxide
|
US8741930B2
(en)
*
|
2008-10-24 |
2014-06-03 |
Bridge Pharma, Inc. |
Treating xerophthalmia with norketotifen
|
US8765787B2
(en)
*
|
2008-11-21 |
2014-07-01 |
Bridge Pharma, Inc. |
Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
|
CA2746810C
(en)
|
2008-12-30 |
2017-03-14 |
Rigel Pharmaceuticals, Inc. |
Pyrimidinediamine kinase inhibitors
|
PT2389372E
(pt)
|
2009-01-23 |
2016-01-07 |
Rigel Pharmaceuticals Inc |
Composições e métodos para a inibição da via jak
|
WO2010091198A1
(en)
|
2009-02-06 |
2010-08-12 |
University Of Southern California |
Therapeutic compositions comprising monoterpenes
|
US8409606B2
(en)
|
2009-02-12 |
2013-04-02 |
Incept, Llc |
Drug delivery through hydrogel plugs
|
JP5738292B2
(ja)
|
2009-07-28 |
2015-06-24 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jak経路の阻害のための組成物および方法
|
US20110033545A1
(en)
*
|
2009-08-06 |
2011-02-10 |
Absize, Inc. |
Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
|
CN104744215B
(zh)
|
2010-03-03 |
2019-03-15 |
尼昂克技术公司 |
包含单萜的药物组合物
|
CA2792950C
(en)
|
2010-04-24 |
2014-02-11 |
Viamet Pharmaceuticals, Inc. |
5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors
|
MX347331B
(es)
|
2010-07-28 |
2017-04-21 |
Rigel Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de la via jak.
|
US9499461B2
(en)
|
2010-08-27 |
2016-11-22 |
Neonc Technologies, Inc. |
Pharmaceutical compositions comprising POH derivatives
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
US8961501B2
(en)
|
2010-09-17 |
2015-02-24 |
Incept, Llc |
Method for applying flowable hydrogels to a cornea
|
EP2632903A4
(de)
|
2010-10-28 |
2014-11-26 |
Viamet Pharmaceuticals Inc |
Metalloenzymhemmerverbindungen
|
ES2703498T3
(es)
|
2010-11-13 |
2019-03-11 |
Innocrin Pharmaceuticals Inc |
1-(6,7-Bis(difluorometoxi)naftalen-2-il)-2-metil-1-(1H-1,2,3-triazol-4-il)propan-1-ol como inhibidor de CYP17 para el tratamiento de enfermedades dependientes de andrógenos como el cáncer de próstata
|
CA2820718A1
(en)
|
2010-12-13 |
2012-06-21 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
US9211269B2
(en)
|
2010-12-17 |
2015-12-15 |
Neonc Technologies Inc. |
Methods and devices for using isoperillyl alcohol
|
US9169182B2
(en)
|
2011-02-25 |
2015-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chrysophaentin analogs that inhibit FtsZ protein
|
EP2701722A4
(de)
|
2011-04-28 |
2014-12-31 |
Univ Southern California |
Aus menschlichen myeloiden suppressorzellen gewonnene krebsmarker
|
EP2721021B1
(de)
|
2011-06-19 |
2019-01-23 |
Viamet Pharmaceuticals (NC), Inc. |
Metalloenzymhemmerverbindungen
|
KR20180095108A
(ko)
|
2011-06-19 |
2018-08-24 |
비아멧 파마슈티컬즈(엔씨), 인코포레이티드 |
금속효소 억제제 화합물
|
JP2014523880A
(ja)
|
2011-06-23 |
2014-09-18 |
ヴィアメット ファーマスーティカルズ,インコーポレイテッド |
金属酵素化合物
|
US10226417B2
(en)
|
2011-09-16 |
2019-03-12 |
Peter Jarrett |
Drug delivery systems and applications
|
CN107011323A
(zh)
|
2011-12-11 |
2017-08-04 |
威尔金制药有限公司 |
金属酶抑制剂化合物
|
CN104136427B
(zh)
|
2012-01-20 |
2017-03-01 |
威尔金制药有限公司 |
金属酶抑制剂化合物
|
WO2013142038A2
(en)
|
2012-03-23 |
2013-09-26 |
Oxigene, Inc. |
Compositions and methods for inhibition of cathepsins
|
US20130310340A1
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
US9982236B2
(en)
|
2013-06-13 |
2018-05-29 |
Orgenesis Ltd. |
Cell populations, methods of transdifferentiation and methods of use thereof
|
MA41296A
(fr)
|
2014-12-30 |
2017-11-07 |
Orgenesis Ltd |
Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
|
WO2016130800A2
(en)
|
2015-02-12 |
2016-08-18 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising perillyl alcohol derivatives
|
AU2016261925B2
(en)
|
2015-05-12 |
2020-10-01 |
Incept, Llc |
Drug delivery from hydrogels
|
EP3719016A1
(de)
|
2015-08-04 |
2020-10-07 |
Rigel Pharmaceuticals, Inc. |
Benzazolverbindungen und verfahren zur herstellung und verwendung der verbindungen
|
JP6803923B2
(ja)
|
2015-12-30 |
2020-12-23 |
エヌキューピー 1598,リミテッド |
金属酵素阻害化合物
|
ES2940911T3
(es)
|
2016-06-27 |
2023-05-12 |
Rigel Pharmaceuticals Inc |
Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4
|
WO2018081294A1
(en)
|
2016-10-26 |
2018-05-03 |
Rigel Pharmaceuticals, Inc. |
Pyrazole amide compounds as irak inhibitors
|
PT3532470T
(pt)
|
2016-10-26 |
2023-02-28 |
Rigel Pharmaceuticals Inc |
Derivados de oxazol para uso como inibidores de irak e método para a sua preparação
|
WO2018102412A1
(en)
|
2016-11-30 |
2018-06-07 |
Neonc Technologies, Inc. |
A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
|
KR20190129034A
(ko)
|
2016-12-29 |
2019-11-19 |
세레니티 테라퓨틱스 (버뮤다), 리미티드 |
금속효소 억제제 화합물
|
EP3562306A4
(de)
|
2016-12-29 |
2020-06-24 |
Selenity Therapeutics (Bermuda), Ltd. |
Metalloenzym-inhibitor-verbindungen
|
EP3635106A4
(de)
|
2017-05-08 |
2021-01-06 |
Orgenesis Ltd. |
Transdifferenzierte zellpopulationen und verfahren zur verwendung davon
|
CA3068305A1
(en)
|
2017-06-29 |
2019-01-03 |
Rigel Pharmaceuticals, Inc. |
Kinase inhibitors and methods for making and using
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
CA3225993A1
(en)
|
2018-02-08 |
2019-08-15 |
University Of Southern California |
The use of monoterpene, sesquiterpene, or their derivatives to permeabilize the blood brain barrier
|
SI3788044T1
(sl)
|
2018-05-03 |
2023-12-29 |
Rigel Pharmaceuticals, Inc. |
Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
|
WO2019213445A1
(en)
|
2018-05-03 |
2019-11-07 |
Rigel Pharmaceuticals, Inc. |
Rip1 inhibitory compounds and methods for making and using the same
|
US20220000880A1
(en)
|
2018-11-01 |
2022-01-06 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
WO2021026451A1
(en)
|
2019-08-08 |
2021-02-11 |
Rigel Pharmaceuticals, Inc. |
Compounds and method for treating cytokine release syndrome
|
MX2022001890A
(es)
|
2019-08-14 |
2022-04-26 |
Rigel Pharmaceuticals Inc |
Metodo para bloquear o mejorar el sindrome de liberacion de citocinas.
|
JP2022545542A
(ja)
|
2019-08-30 |
2022-10-27 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
ピラゾール化合物、その製剤並びに化合物及び/又は製剤を使用する方法
|
CA3149729A1
(en)
|
2019-09-06 |
2021-03-11 |
Yan Chen |
Rip1 inhibitory compounds and methods for making and using the same
|
CN114761398A
(zh)
|
2019-09-06 |
2022-07-15 |
里格尔药品股份有限公司 |
杂环rip1激酶抑制剂
|
JP7395730B2
(ja)
|
2019-11-07 |
2023-12-11 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
ヘテロ環式rip1阻害化合物
|
US20220288047A1
(en)
|
2021-03-03 |
2022-09-15 |
Rigel Pharmaceuticals, Inc. |
Method for treating a disease or condition using a pyrazole compound or formulation thereof
|
AR125587A1
(es)
|
2021-03-11 |
2023-08-02 |
Rigel Pharmaceuticals Inc |
Inhibidores heterocíclicos de la quinasa de rip1
|
US20230303555A1
(en)
|
2022-03-23 |
2023-09-28 |
Rigel Pharmaceuticals, Inc. |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
US20230312568A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|